See how EMET supports cross-functional teams working across strategy, science, reporting, and evidence interpretation.
Cross-functional capabilities
Explore a range of sample prompts and representative outputs from EMET across the workflows below.
Summarize the clinical and mechanistic evidence for targeting TREM2 in Alzheimer's disease. What are the key unresolved questions?
PubMedEurope PMCbioRxivKTMineSemantic Scholar
Give me a competitive and IP landscape for KRAS G12C inhibitors - active trials, approved drugs, key patent holders, and upcoming data readouts.
KTMineClinicalTrials.govPubMedpreprints
Give me a full target profile for CDK4 - mechanism, tissue expression, druggability, known inhibitors with clinical data, and key safety considerations.
PharosOpen TargetsChEMBLUniProtDrugMechDB
What are the pharmacogenomic considerations for clopidogrel? Which patient populations are at risk of treatment failure, what variants drive this, and how should dosing be adjusted?
GWAS CataloggnomADClinVarPharmGKBPan-UKBB
I am designing a Phase 2 trial in MASH (NASH). What endpoints are currently accepted by FDA and EMA, what are the active Phase 3 trials using, and what is the expected placebo response rate in histological endpoints?
Build a forest plot comparing overall survival hazard ratios across the major PD-1/PD-L1 checkpoint inhibitor trials in first-line non-small cell lung cancer, and generate a slide deck summarizing the evidence for our medical affairs team.
I have a list of 50 genes upregulated in treatment-resistant breast cancer vs sensitive tumors from a DEG analysis. Run pathway enrichment and build the protein interaction network for the top hits. What biological processes are driving resistance?
ReactomeSTRINGGOKEGGBioGRID
Build a portfolio dashboard for our 8 oncology targets - pull the latest GO/NO-GO status from our internal assay tracker via API, overlay the published clinical evidence, and flag any targets where the competitive landscape has changed in the last 90 days.
